Navigation Links
Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment
Date:8/17/2008

SYDNEY, Australia, Aug. 17 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the first pivotal Phase 3 clinical trial of Bronchitol for the treatment of cystic fibrosis has completed enrolment.

The first efficacy data from the trial is expected to be available during the first half of 2009. The trial commenced its dosing phase in April 2007, reached its initial recruitment target of 250 subjects in June 2008 and closed today with 325 subjects enrolled. Recruitment was extended to cater for a lower numbers of patients than anticipated entering the study on rhDNASE.

The trial is a double blind, comparator controlled, randomised study comparing 400 mg of Bronchitol twice a day to control. The trial includes a 26-week efficacy and safety component, followed by a 26 week open-label Bronchitol safety extension.

The primary efficacy end-point is change from baseline in FEV1 (forced expiratory volume in one second) after 26 weeks.

Pharmaxis Chief Executive Officer Alan Robertson said: "It is rewarding to reach this milestone in bringing Bronchitol to the marketplace. The study has enrolled well, and we look forward to the results helping to shape cystic fibrosis clinical practice in the future."

Pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Food and Drug Administration and Orphan Drug Designation from the European Medicines Agency for Bronchitol in cystic fibrosis.

Bronchitol is designed to hydrate the airway surface of the lungs, improve lung hygiene and promote normal lung clearance.

Approximately 75,000 people in the major pharmaceutical markets are affected with cystic fibrosis and no products have been approved to improve lung hydration.

To find out more about Pharmaxis, go to http://www.pharmaxis.com.au .

Forward-Looking Statements

The statements contained in thi
'/>"/>

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Bronchitol Cystic Fibrosis Dose Trial Results Positive
2. Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
3. Pharmaxis Establishes Named Patient Program for Bronchitol
4. Pharmaxis Long-Term Safety Study of Bronchitol Completes
5. Nuvelo Announces Positive Phase 1b Proof-of-Concept Data With Anticoagulant NU172
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... CVS Caremark Corporation (NYSE: CVS ) announced today ... in connection with its previously announced cash tender offers (the ... and all of its 6.250% Senior Notes due 2027 (the ... amount of its 6.125% Senior Notes due 2039, 5.750% Senior ... the "Maximum Tender Offer Notes" and together with the Any ...
(Date:8/21/2014)... /CNW/ - Bedrocan Cannabis Corp., previously Bedrocan Canada Inc. ... Board of Directors, enhancing executive oversight and strengthening ... leading licensed producer of medicinal cannabis in ... years, experience in producing and supplying government-regulated pharmaceutical-grade ... As previously announced in a ...
(Date:8/21/2014)... , Aug. 21, 2014  SI-BONE, Inc. ( ... that pioneered the use of the iFuse Implant System, ... for fusion of the sacroiliac (SI) joint, announced that ... update to its Lumbar Fusion Medical Policy No. 91590-R4 ... procedure.  The policy states that the fusion procedure, which ...
Breaking Medicine Technology:CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3
... QPT: TSX Venture Exchange, EDMONTON, May 02, 2007 ... Quest is pleased to provide an,update on the ... cancer. , Prostate cancer is the second leading ... 230,000 new cases and 30,000 deaths,per year. Current ...
... 2007 - Acorda Therapeutics, Inc.(R),(Nasdaq: ACOR) today ... trial,of Fampridine-SR in people with multiple sclerosis ... Andrew Goodman, M.D.,Director of the Multiple Sclerosis ... results on walking ability, leg,strength, spasticity and ...
Cached Medicine Technology:Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 2Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 3Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 4Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 5Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 6Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting 7
(Date:8/21/2014)... August 21, 2014 It's a terrible thing ... road to a serious substance abuse issue. When that happens ... of action is getting reliable help from the qualified substance ... right facility isn’t always easy for those young adults living ... a significant addiction issue. , Thankfully there is a ...
(Date:8/21/2014)... Angeles, CA (PRWEB) August 21, 2014 Sleep ... doctors across the U.S. This provides doctors with a convenient ... who find a doctor are that much closer to finding ... condition have no idea they are experiencing this sleep ... not receive treatment at all. , Thanks to Sleep Apnea ...
(Date:8/21/2014)... ERT, a leading global ... efficacy endpoint data collection, today opened registration ... Maximizing Product Value with Optimized Endpoints. ... biopharmaceutical developers to network with leading researchers ... developing, implementing, and justifying effective strategies for ...
(Date:8/21/2014)... shirt do we put on in the morning? Do we ... joint do we want to buy lunch? We make hundreds ... have a minimal impact, it is extremely important for our ... as possible. People with ADHD often find this difficult, however. ... which bring a prompt but smaller reward instead of making ...
(Date:8/21/2014)... 2014 Bedros Keuilian’s Annual Fitness Business Summit ... attended by many people already earning seven-figure incomes. But his ... usually only open to the owners of Keuilian’s own international ... year’s Fit Body Boot Camp World Conference will also be ... fitness boot camp or are struggling with their own ...
Breaking Medicine News(10 mins):Health News:Young Adults in Pompano Beach, FL Are Finding Success With Innovative New Helpline 2Health News:Sleep Apnea Doctors US is Now Offering Complimentary Listings to Sleep Apnea Doctors Across the United States 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 2Health News:ERT Opens Registration for PROFICIENCY™ Regional Conference Series 3Health News:ADHD children make poor decisions due to less differentiated learning processes 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 2Health News:Fitness Boot Camp Founder Offers Fifty Scholarships to Fit Body Boot Camp World Conference 3
... 22 Weight Watchers,International, Inc. (NYSE: WTW ) ... a written plan for the purpose of,selling limited amounts ... adopted in accordance with Rule 10b5-1 of the Securities ... to exercise stock,options to diversify his holdings for financial ...
... in hemodialysis patients , , FRIDAY, Feb. 22 (HealthDay News) ... control in people with diabetes gives inaccurate results for ... Hemodialysis, used to treat patients with kidney failure, involves ... machine. , This Wake Forest University Baptist Medical ...
... The following statement,was issued today by William ... Kids:, The Nebraska Legislature has delivered a ... breathe clean air by passing legislation to make,all ... urge Governor Dave Heineman to sign into law ...
... ATLANTA, Feb. 22 Rarely written about, seldom spoken,of, ... the,lives of an astonishing 40% of women and 25% ... and turn what once were ordinary,tasks and activities into ... of 3, found the varicose veins significantly,affected her life ...
... Women of the United States, we,double dare you! ... your risk of cardiovascular disease., Who,s laying down ... the,American Heart Association has challenged women across the country ... to reduce their risks.,RealAge.com, the nation,s leading healthy-lifestyle Web ...
... Mo. More than $1.1 billion a year is spent ... Missouri study reports the state has a rising number of ... with hunger. The MU Interdisciplinary Center for Food Security has ... first Missouri Hunger Atlas details the distribution of hunger in ...
Cached Medicine News:Health News:Weight Watchers COO Adopts 10b5-1 Trading Plan 2Health News:Current Blood Sugar Control Test Results 'Inaccurate' 2Health News:Approval of Nebraska Smoke-Free Legislation is Historic Win for Health 2Health News:Beyond Vanity: New Treatment Brings Relief to Women After Years of Silent Suffering 2Health News:American Heart Month Double Dares Women to Beat Health Foes 2Health News:MU research team releases first Missouri Hunger Atlas 2
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
... manufactured for use as a diluent for ... is for use on the Coulter® Counter ... IV, V, VI with three-part differential and ... The shelf life is two years from ...
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... 12 Plus Retics is a 5-part differential ... for the Abbott CELL-DYN 3200, 3500, 3700 ... also contains nucleated red blood cells that ... CELL-DYN 4000. The assay contains automated and ...
Medicine Products: